SM1
MCID: SCH060
MIFTS: 38

Schistosoma Mansoni Infection, Susceptibility/ (SM1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 57
Schistosoma Mansoni Infection, Susceptibility/resistance to 57 13
Schistosomiasis 58 70
Sm1 57 17
Schistosoma Mansoni, Intensity of Infection by; Sm1 57
Schistosoma Mansoni, Intensity of Infection by 57
Bilharziasis 58

Characteristics:

Orphanet epidemiological data:

58
schistosomiasis
Inheritance: Not applicable; Age of onset: All ages;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM® 57 181460
MESH via Orphanet 45 D012552
ICD10 via Orphanet 33 B65.0 B65.1 B65.2 more
UMLS via Orphanet 71 C0036323
Orphanet 58 ORPHA1247
MedGen 41 C1866993
SNOMED-CT via HPO 68 263681008
UMLS 70 C0036323

Summaries for Schistosoma Mansoni Infection, Susceptibility/

MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to schistosomiasis and intestinal schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Albendazole and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and spleen, and related phenotype is abnormality of the immune system.

More information from OMIM: 181460

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 583)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 12.0
2 intestinal schistosomiasis 11.8
3 urinary schistosomiasis 11.7
4 cercarial dermatitis 11.3
5 pulmonary arterial hypertension associated with schistosomiasis 11.2
6 neuroschistosomiasis 11.1
7 hepatic fibrosis, severe due to schistosoma mansoni infection 10.9
8 portal hypertension 10.8
9 splenomegaly 10.8
10 varicose veins 10.7
11 hypereosinophilic syndrome 10.6
12 parasitic helminthiasis infectious disease 10.6
13 liver cirrhosis 10.6
14 bladder cancer 10.6
15 fibrosis of extraocular muscles, congenital, 1 10.6
16 esophageal varix 10.5
17 pulmonary hypertension 10.5
18 diarrhea 10.5
19 filariasis 10.5
20 malaria 10.5
21 proteinuria, chronic benign 10.5
22 allergic disease 10.4
23 appendicitis 10.4
24 fascioliasis 10.4
25 disease by infectious agent 10.4
26 pulmonary hypertension, primary, 1 10.4
27 myelitis 10.4
28 paragonimiasis 10.4
29 viral hepatitis 10.4
30 ancylostomiasis 10.3
31 liver disease 10.3
32 filarial elephantiasis 10.3
33 clonorchiasis 10.3
34 hepatitis c 10.3
35 transverse myelitis 10.3
36 hepatitis b 10.3
37 urinary tract obstruction 10.3
38 hydronephrosis 10.3
39 onchocerciasis 10.3
40 cystitis 10.3
41 glomerulonephritis 10.3
42 strongyloidiasis 10.3
43 infertility 10.3
44 cytokine deficiency 10.3
45 kala-azar 1 10.3
46 portal vein thrombosis 10.3
47 leishmaniasis 10.3
48 salmonellosis 10.3
49 hypersplenism 10.3
50 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:



Diseases related to Schistosoma Mansoni Infection, Susceptibility/

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 31 HP:0002715

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Immunology:
schistosoma mansoni infection susceptibility/resistance

Clinical features from OMIM®:

181460 (Updated 20-May-2021)

Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
2
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
3
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
4
Triclabendazole Approved, Investigational Phase 3 68786-66-3
5
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
6
Piperaquine Approved, Experimental, Investigational Phase 3 4085-31-8 5079497
7
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
8
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
10 Tubulin Modulators Phase 3
11 Antimitotic Agents Phase 3
12 Antimalarials Phase 3
13 Antiprotozoal Agents Phase 3
14 Folic Acid Antagonists Phase 3
15 Vitamin B9 Phase 3
16 Vitamin B Complex Phase 3
17 Folate Phase 3
18 Fanasil, pyrimethamine drug combination Phase 3
19 Antiviral Agents Phase 3
20
Lumefantrine Approved Phase 2 82186-77-4 6437380
21
Artemether Approved Phase 2 71963-77-4 119380 9796294 68911
22
Epoprostenol Approved Phase 2 61849-14-7, 35121-78-9 5280427 5282411
23
Selexipag Approved Phase 2 475086-01-2
24
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
25
Pyronaridine Investigational Phase 2 74847-35-1 5485198
26
Tezosentan Investigational Phase 2 180384-57-0
27
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795
28 Artemisinins Phase 2
29 Artemether, Lumefantrine Drug Combination Phase 2
30 Artemisinine Phase 2
31 Ferroquine Phase 2
32 Antihypertensive Agents Phase 2
33 Vaccines Phase 1, Phase 2
34 Gastrointestinal Agents Phase 1, Phase 2
35 Adjuvants, Immunologic Phase 1, Phase 2
36 Antacids Phase 1, Phase 2
37 Anti-Ulcer Agents Phase 1, Phase 2
38 Immunologic Factors Phase 1, Phase 2
39 Pharmaceutical Solutions Phase 1, Phase 2
40
Aluminum sulfate Approved Phase 1 10043-01-3
41 Immunoglobulins Phase 1
42 Antibodies Phase 1
43
Sodium citrate Approved, Investigational 68-04-2
44 Mango Approved
45
Iron Approved 7439-89-6 23925 29936
46
Ciprofloxacin Approved, Investigational 85721-33-1 2764
47
Cefuroxime Approved 55268-75-2 5361202 5479529
48
Metronidazole Approved 443-48-1 4173
49
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
50
Azithromycin Approved 83905-01-5 55185 447043

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
7 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
8 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Completed NCT04115072 Phase 2, Phase 3 Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1
12 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Completed NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
13 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
14 An Open Label, Phase III Efficacy and Safety Study of L-PZQ ODT in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
15 Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection Completed NCT04264130 Phase 2 Artesunate-Pyronaridine;Artemether-Lumefantrine;Artefenomel-Ferroquine
16 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
17 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
18 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
19 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Completed NCT03799510 Phase 2 GLA-SE solution
20 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
21 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
22 Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Recruiting NCT04589390 Phase 2 Selexipag
23 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Recruiting NCT03910972 Phase 1, Phase 2
24 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
25 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
26 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
27 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Completed NCT03110757 Phase 1
28 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
29 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
30 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
31 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
32 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
33 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
34 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
35 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593
36 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
37 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
38 Women and Childres at the Focal Point for the Schistosomiasis Control and Sustainability and Effectiveness in the Hydro Agricultural Zone of Sourou, Burkina Faso Completed NCT00463528
39 A Randomized Control Study to Evaluate Novel Interventions to Reduce Risk Factors Associated With HIV, Neglected Tropical and Non-communicable Diseases Among Couples in Zambia Completed NCT02744586
40 Study of Reproductive Health in Rural Madagascar With Emphasis on Urogenital Schistosomiasis and Sexually Transmitted Infections Completed NCT00713999 Treatment with anti-STI and anti-schistosoma regimens
41 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
42 Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease Completed NCT00138450
43 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
44 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410
45 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
46 Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Completed NCT02495909
47 Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Completed NCT00463931
48 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
49 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
50 Detection of Schistosomiasis Circulating Anodic Antigen (CAA) in Travellers After High-risk Water Contact Completed NCT02194712

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Praziquantel

Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

40
Liver, Spinal Cord, Spleen, Skin, T Cells, Kidney, Colon

Publications for Schistosoma Mansoni Infection, Susceptibility/

Articles related to Schistosoma Mansoni Infection, Susceptibility/:

(show top 50) (show all 16804)
# Title Authors PMID Year
1
Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. 61 57
10441577 1999
2
Absence of linkage between MHC and a gene involved in susceptibility to human schistosomiasis. 57 61
9698772 1998
3
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 57 61
8841190 1996
4
Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. 61 57
1902058 1991
5
Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. 57
21059925 2010
6
Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. 57
16301741 2005
7
Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 57
10094195 1999
8
Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni. 57
9311752 1997
9
Deubiquitinating enzymes as possible drug targets for schistosomiasis. 61
33577811 2021
10
Adherence to diagnosis followed by selective treatment of schistosomiasis mansoni and related knowledge among schoolchildren in an endemic area of Minas Gerais, Brazil, prior to and after the implementation of educational actions. 61
33732914 2021
11
Prevalence and incidence of advanced schistosomiasis and risk factors for case fatality in Hunan Province, China. 61
33617765 2021
12
Evaluation of Schistosomiasis Mansoni Morbidity by Hepatic and Splenic Elastography. 61
33618959 2021
13
Low specificity of point-of-care circulating cathodic antigen (POCCCA) diagnostic test in a non-endemic area for schistosomiasis mansoni in Brazil. 61
33587944 2021
14
Transcriptional profiles of genes potentially involved in extracellular vesicle biogenesis in Schistosoma japonicum. 61
33524382 2021
15
Diagnostic comparison of stool exam and point-of-care circulating cathodic antigen (POC-CCA) test for schistosomiasis mansoni diagnosis in a high endemicity area in northeastern Brazil. 61
33190646 2021
16
Evaluation of a real-time recombinase polymerase amplification assay for rapid detection of Schistosoma haematobium infection in resource-limited setting. 61
33497617 2021
17
Characterization of class II fumarase from Schistosoma mansoni provides the molecular basis for selective inhibition. 61
33549669 2021
18
High-resolution AP-SMALDI MSI as a tool for drug imaging in Schistosoma mansoni. 61
33723627 2021
19
Association of previous schistosome infection with fatty liver and coronary heart disease: A cross-sectional study in china. 61
33454990 2021
20
Structural Requirements for Dihydrobenzoxazepinone Anthelmintics: Actions against Medically Important and Model Parasites: Trichuris muris, Brugia malayi, Heligmosomoides polygyrus, and Schistosoma mansoni. 61
33797218 2021
21
Revisiting the Schistosoma japonicum life cycle transcriptome for new insights into lung schistosomula development. 61
33548219 2021
22
In vitro and in vivo evaluation of cnicin from blessed thistle (Centaurea benedicta) and its inclusion complexes with cyclodextrins against Schistosoma mansoni. 61
33164156 2021
23
Prevalence and risk factors of Schistosoma mansoni infection among preschool-aged children from Panamasso village, Burkina Faso. 61
33794961 2021
24
IN VITRO AND IN VIVO EFFECTS OF P-MAPA IMMUNOMODULATOR ON SCHISTOSOMIASIS. 61
33789153 2021
25
Patients with severe schistosomiasis mansoni in Ituri Province, Democratic Republic of the Congo. 61
33762007 2021
26
The Coutinho index as a simple tool for screening patients with advanced forms of Schistosomiasis mansoni: a validation study. 61
33728455 2021
27
Pleural schistosomiasis masquerading as tubercular pyopneumothorax: World's first case report. 61
33687014 2021
28
Use of Schistosoma mansoni soluble egg antigen (SEA) for antibody detection and diagnosis of schistosomiasis: The need for improved accuracy evaluations of diagnostic tools. 61
33352167 2021
29
Population-based, spatiotemporal modeling of social risk factors and mortality from schistosomiasis in Brazil between 1999 and 2018. 61
33753030 2021
30
EDTA-dependent pseudothrombocytopenia in patients with hepatosplenic schistosomiasis mansoni: a clinical management alert. 61
33690852 2021
31
Potato apyrase reduces granulomatous area and increases presence of multinucleated giant cells in murine schistosomiasis. 61
33676013 2021
32
Urological management and surgical procedures in migrants from Sub-Saharan Africa with urogenital schistosomiasis. 61
33685664 2021
33
Prevalence of schistosomiasis and its association with anemia among pregnant women: a systematic review and meta-analysis. 61
33653391 2021
34
Epigenetic Markers Associated with Schistosomiasis. 61
33664616 2021
35
Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies. 61
33515038 2021
36
Evaluation of microscopy, serology, circulating anodic antigen (CAA), and eosinophil counts for the follow-up of migrants with chronic schistosomiasis: a prospective cohort study. 61
33750443 2021
37
Validity of urine-CCA cassette test and indirect haem-agglutination assay (IHA) in the detection of schistosomiasis-mansoni infection relative to microscopic examination. 61
33746416 2021
38
Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature. 61
33764979 2021
39
Five key points about intestinal schistosomiasis for the migrant health practitioner. 61
33444785 2021
40
Association of TNF (rs1800629) promoter polymorphism and schistosomiasis with sub-microscopic asymptomatic Plasmodium falciparum infections in a schistosomiasis-endemic area in Zimbabwe. 61
33191564 2021
41
Clinicopathologic Features of Chronic Intestinal Schistosomiasis and Its Distinction From Crohn Disease. 61
32991343 2021
42
Hepatocyte CD1d protects against liver immunopathology in mice with schistosomiasis japonica. 61
33283278 2021
43
Vesical schistosomiasis, an emerging cause of gross hematuria in developed countries. 61
33446457 2021
44
Imported schistosomiasis in Paris region of France: A multicenter study of prevalence and diagnostic methods. 61
33785455 2021
45
Liver stiffness is able to differentiate hepatosplenic Schistosomiasis mansoni from liver cirrhosis and spleen stiffness may be a predictor of variceal bleeding in hepatosplenic schistosomiasis. 61
33728472 2021
46
History of Human Schistosomiasis (bilharziasis) in China: From Discovery to Elimination. 61
33713275 2021
47
Cell therapy as a new approach on hepatic fibrosis of murine model of Schistosoma mansoni-infection. 61
32816183 2021
48
STAT3: A key regulator in liver fibrosis. 61
32702499 2021
49
Circulating cell-free mitochondrial DNA fragment: A possible marker for early detection of Schistosoma japonicum. 61
33348056 2021
50
The potent effect of silymarin combination with Praziquantel or mirazid for Schistosoma mansoni treatment in infected male swiss albino mice. 61
33797519 2021

Variations for Schistosoma Mansoni Infection, Susceptibility/

Expression for Schistosoma Mansoni Infection, Susceptibility/

Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.

Pathways for Schistosoma Mansoni Infection, Susceptibility/

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

Sources for Schistosoma Mansoni Infection, Susceptibility/

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....